CBD Extract Suppressed Immune Cell Activation More Effectively Than Standard Immunosuppressants in Lab Tests | Research

The takeaway

A CBD-rich cannabis extract outperformed dexamethasone and tacrolimus at suppressing T cell activation, inflammatory cytokines, and cytotoxic molecule expression in vitro.

Immunology researchers, dermatologists, transplant medicine specialists, anyone interested in CBD's anti-inflammatory potential

CBD extract reduced Granzyme B by 81-82% and nearly eliminated inflammatory cytokines in T cells

What the researchers found

The CBD-rich extract CAN296 reduced T cell activation markers (CD69) to 2-11% in CD4+ cells and 5-17% in CD8+ cells. It nearly eliminated TNF-alpha and IFN-gamma secretion in CD8+ cells at all tested doses. These effects were more potent and consistent than either dexamethasone or tacrolimus.

Why it matters

Oral lichen planus and graft-versus-host disease are T cell-driven conditions with limited treatment options. The finding that a CBD-rich extract outperformed two standard immunosuppressants at controlling T cell activity suggests a potential new therapeutic approach for these conditions.

The numbers in context

CD69 reduced to 2-11% in CD4+ and 5-17% in CD8+ T cells; TNF-alpha and IFN-gamma nearly undetectable in CD8+ cells at all CAN296 doses; Granzyme B reduced 81-82%; Perforin reduced 40-53%; Fas-L reduced 40-44%; tacrolimus paradoxically increased IFN-gamma at lower concentrations

How the study worked

CD4+ and CD8+ T cells isolated from healthy donors were treated with a CBD-rich cannabis extract (CAN296) at three doses and compared to dexamethasone and tacrolimus. Researchers measured T cell activation, cytokine secretion (TNF-alpha, IFN-gamma), and cytotoxic molecule expression (Granzyme B, Perforin, Fas-L).

What this study cannot tell us

In vitro study using cells from healthy donors only, cannot predict clinical efficacy or safety, specific CBD-rich extract (CAN296) may not represent all CBD products, dose ranges may not correspond to achievable tissue concentrations in patients

How to read the evidence

In vitro study with healthy donor cells; strong lab results but no clinical validation yet

When this study was published

Published 2025

The bigger picture

Standard immunosuppressants like dexamethasone and tacrolimus come with significant side effects. If CBD-rich extracts can match or exceed their efficacy at controlling immune responses, this could open a pathway to treatments with potentially fewer adverse effects.

Questions still open

Would CAN296 show similar immunosuppressive effects in patients with oral lichen planus or graft-versus-host disease? What formulation and dosing would achieve effective tissue concentrations? How does the extract compare to isolated CBD?

Common questions

How did CBD compare to standard immunosuppressants in this study?

The CBD-rich extract was more potent and consistent than both dexamethasone and tacrolimus at suppressing T cell activation and inflammatory cytokine production in lab tests.

Could CBD replace immunosuppressant drugs?

These are lab results only. While the CBD extract outperformed standard drugs in vitro, clinical trials in patients are needed before any conclusions about replacing existing treatments.

Read the original research

Immunomodulatory Effects of a High-CBD Cannabis Extract: A Comparative Analysis with Conventional Therapies for Oral Lichen Planus and Graft-Versus-Host Disease.

International journal of molecular sciences, 26(21)

View on PubMed ↗Publisher’s paper ↗

Citation

Blal, Kifah; Rosenblum, Ronen; Novak-Kotzer, Hila; Procaccia, Shiri; Abu Tair, Jawad; Casap, Nardy; Meiri, David; Benny, Ofra. (2025). Immunomodulatory Effects of a High-CBD Cannabis Extract: A Comparative Analysis with Conventional Therapies for Oral Lichen Planus and Graft-Versus-Host Disease.. International journal of molecular sciences, 26(21). https://doi.org/10.3390/ijms262110711